

REMARKS

In response to the Restriction Requirement mailed on May 31, 2006, Applicants elect Embodiment II for further prosecution. Applicants also elect SEQ ID NO:1 with traverse. Applicants submit herewith a Request for Extension of Time of two months thereby extending the period for response from July 1, 2006 to August 31, 2006. The undersigned hereby authorizes the charge of any fees created by the filing of this document or any deficiency of fees submitted herewith to be charged to deposit account No. 19-1970.

Claims 1-68 have been canceled and new claims 69-78 submitted.

Claims 69-71, 73 and 75-76 substantially track canceled claim 50.

Claim 72 is drawn to nucleic acid molecules encoding a protein 80% identical to specified SEQ ID NO's. Support for such nucleic acid molecules can be found in the specification, for example, on page 33, lines 3-6.

Claims 77 and 78 are drawn to fragments of nucleic acid molecules consisting of specific sequences. Support for such fragments can be found in the specification, for example, on page 39, lines 13-24, and on page 35, lines 29-31, through page 36, lines 1-6.

Accordingly, Applicants submit that no new matter has been entered in to the Application.

I. Group Election

Applicants have elected Embodiment II, drawn to isolated nucleic acid sequences and therapeutic compositions comprising such nucleic acid sequences, for further prosecution.

II. Sequence Election

Applicants have elected SEQ ID NO:1, with traverse, for further prosecution. SEQ ID NO:1 is a full length nucleic acid molecule the complement of which is SEQ ID NO:3. The protein encoded by SEQ ID NO:1 is represented by SEQ ID NO:2.

Applicants request the Examiner rejoin SEQ ID NO:1 with SEQ ID NO:28, it's corresponding complement SEQ ID NO:30, and with SEQ ID NO:50. As noted above, SEQ ID NO:1 is a full-length nucleic acid molecule encoding the V, D and J regions of a canine T-cell

receptor β chain. SEQ ID NO:28 is a truncated version of SEQ ID NO:1 and consequently is identical over its entire length to the corresponding region of SEQ ID NO:1. Furthermore, SEQ ID NO:50 is an oligonucleotide sequence identical in sequence to nucleotides 157-175 of SEQ ID NO:1 and SEQ ID NO:28. The relationship between these molecules is made clear by the following alignment:

SIN1	ATCGGACTCC	TCTGTGGTGT	GGCCTTTTGT	TTCCTGGGAG	TAGGCCTTTT
SIN28	ATCGGACTCC	TCTGTGGTGT	GGCCTTTTGT	TTCCTGGGAG	TAGGCCTTTT
SIN1	GAACGCACAA	GTGACTCAAA	CCCCGAGACA	ACTCATCAAA	AAAGTGGGAG
SIN28	GAACGCACAA	GTGACTCAAA	CCCCGAGACA	ACTCATCAAA	AAAGTGGGAG
SIN1	CGAAAGTTTT	GTTGAAATGT	TCACAGAATA	TGGACCATGA	AAGAATGTTC
SIN28	CGAAAGTTTT	GTTGAAATGT	TCACAGAATA	TGGACCATGA	AAGAATGTTC
SIN1	TGGTATCGAC	AAGACCCAGG	TCTGGGGTTG	CGGCTGCTCT	ACTGGTCCTA
SIN28	TGGTATCGAC	AAGACCCAGG	TCTGGGGTTG	CGGCTGCTCT	ACTGGTCCTA
SIN50		CGAC	AAGACCCAGG	TCTGG	
SIN1	TAATATTGAC	AGTGTTGAGA	CAGGAGACAT	CCCTTATGGG	TACAGTGTCT
SIN28	TAATATTGAC	AGTGTTGAGA	CAGGAGACAT	CCCTTATGGG	TACAGTGTCT
SIN1	CGAGGAAGAA	GAAGGATGCC	TTCCCCTTGA	TTCTGGAGTC	TGCTCGCATC
SIN28	CGAGGAAGAA	GAAGGATGCC	TTCCCCTTGA	TTCTGGAGTC	TGCTCGCATC
SIN1	AACCAGACAT	CTGTGTACTT	CTGCGCCAGC	AGCccggttta	gccaaaatac
SIN28	AACCAGACAT	CTGTGTACTT	CTGCGCCAGC	AGC.....
SIN1	ccagtacttc	ggggcgggca	cccggctgct	a	
SIN28	

It is clear from the above that SEQ ID NO:1, SEQ ID NO:28 and SEQ ID NO:50 are identical over their entire lengths to the corresponding region of SEQ ID NO:1. Consequently, SEQ ID NO:3 and SEQ ID NO:30, which are the complements of SEQ ID NO's 1 and 28, respectively, are also identical in their overlapping regions. Thus, Applicants request that SEQ ID NO's 1, 3, 28 and 30, and the proteins encoded by these sequences (i.e., SEQ ID NO:2 and SEQ ID NO:29) be rejoined and examined together since Applicants contend such a search would not pose an undue burden on the Examiner.

Applicants further request SEQ ID NO's 60-61 be rejoined and Examined with SEQ ID NO's 1, 2, 3, 28, 29, 30 and 50. As noted above, SEQ ID NO's 2 and 29 represent the amino acid sequence of the V, D and J regions of a canine T-cell receptor. As noted in the specification, for example, on page 18, lines 4-19, it is known in the art that the sequence between the V and D regions can vary. Thus SEQ ID NO's 60-62, which represent sequence from the carboxyl end of the V region, are substantially identical to SEQ ID NO's 2 and 29 as shown in the following alignment:

SIN2	IGLLCGVAF	FLGVGLLNAQ	VTQTPRQLIK	KVGAKVLLKC	SQNMDHERMF
SIN29	IGLLCGVAF	FLGVGLLNAQ	VTQTPRQLIK	KVGAKVLLKC	SQNMDHERMF
SIN60	IGLLCGVAF	FLGVGLLNAQ	VTQTPRQLIK	KVGRKVLLKC	SQNMDHER..
SIN61	IGLLCGVAF	FLGVGLLNAQ	VTQTPRQLIK	KVGRKVLLKC	SQNMDHER..
SIN62	IGLLCGVAF	FLGVGLLNAQ	VTQTPRQLIK	KVGRKVLLKC	SQNMDHER..
SIN2	WYRQDPGLGL	RLLYWSYNID	SVETGDIPYGYSVS
SIN29	WYRQDPGLGL	RLLYWSYNID	SVETGDIPYGYSVS
SIN60WSYNID	SVETGDIPYG	MFWYQQDPGL	GLRLLYYSVS
SIN61WSYNID	SVETGDIPYG	MFWYQQDPGL	GLRLLYYSVS
SIN62WSYNID	SVETGDIPYG	MFWYQQDPGL	GLRLLYYSVS
SIN2	RKKKDAFPLI	LESARINQTS	VYFCASSpfs	qntqyfgagt	rll
SIN29	RKKKDAFPLI	LESARINQTS	VYFCASS...
SIN60	RKKKDAFPLI	LESARINQTS	VYFCx.....
SIN61	RKKKDAFPLI	LESARINQTS	VYFCxx.....
SIN62	RKKKDAFPLI	LESARINQTS	VYFCxxx....

The above makes it clear that SEQ ID NO's 60-62 are substantially identical to SEQ ID NO's 2 and 29. Applicants therefore request the Examiner rejoin SEQ ID NO's 60-62, and in particular nucleic acid sequences encoding these sequences, with SEQ ID NO's 1-3, 28-30 and 50 since Applicants contend a search for all of these molecules would be co-extensive and would not pose an undue burden on the Examiner.

CONCLUSION

Applicants believe all of the claims to be in condition for allowance. If it would be helpful to obtain favorable consideration of this case, the Examiner is encouraged to call and discuss this case with the undersigned.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: /Darla G. Yoerg/

Darla G. Yoerg
Registration No. 48,053
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
(303) 863-9700

Date: August 30, 2006